Trial Review

Did you know?

The ANZCTR now automatically displays published trial results and simplifies the addition of trial documents such as unpublished protocols and statistical analysis plans.

These enhancements will offer a more comprehensive view of trials, regardless of whether their results are positive, negative, or inconclusive.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/study/NCT05882045




Registration number
NCT05882045
Ethics application status
Date submitted
22/05/2023
Date registered
31/05/2023
Date last updated
15/10/2024

Titles & IDs
Public title
A Study of Retatrutide (LY3437943) in Participants With Obesity and Cardiovascular Disease
Scientific title
A Randomized, Double-Blind, Phase 3 Study to Investigate the Efficacy and Safety of LY3437943 Once Weekly Compared to Placebo in Participants With Severe Obesity and Established Cardiovascular Disease
Secondary ID [1] 0 0
J1I-MC-GZBM
Secondary ID [2] 0 0
18582
Universal Trial Number (UTN)
Trial acronym
TRIUMPH-3
Linked study record

Health condition
Health condition(s) or problem(s) studied:
Obesity 0 0
Cardiovascular Diseases 0 0
Condition category
Condition code
Diet and Nutrition 0 0 0 0
Obesity
Metabolic and Endocrine 0 0 0 0
Other metabolic disorders

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - Retatrutide
Treatment: Drugs - Placebo

Experimental: Retatrutide Dose 1 - Participants will receive retatrutide subcutaneously (SC).

Experimental: Retatrutide Dose 2 - Participants will receive retatrutide SC.

Placebo comparator: Placebo - Participants will receive placebo.


Treatment: Drugs: Retatrutide
Administered SC

Treatment: Drugs: Placebo
Administered SC
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Percent Change from Baseline in Body Weight
Timepoint [1] 0 0
Baseline, Week 80
Secondary outcome [1] 0 0
Change from Baseline in Body Mass Index (BMI)
Timepoint [1] 0 0
Baseline, Week 80
Secondary outcome [2] 0 0
Change from Baseline in Waist Circumference
Timepoint [2] 0 0
Baseline, Week 80
Secondary outcome [3] 0 0
Percent Change from Baseline in Total Cholesterol
Timepoint [3] 0 0
Baseline, Week 80
Secondary outcome [4] 0 0
Percent Change from Baseline in Triglycerides
Timepoint [4] 0 0
Baseline, Week 80
Secondary outcome [5] 0 0
Change from Baseline in Systolic Blood Pressure (SBP)
Timepoint [5] 0 0
Baseline, Week 80
Secondary outcome [6] 0 0
Change from Baseline in Diastolic Blood Pressure (DBP)
Timepoint [6] 0 0
Baseline, Week 80
Secondary outcome [7] 0 0
Change from Baseline in Hemoglobin A1c (HbA1c)
Timepoint [7] 0 0
Baseline, Week 80
Secondary outcome [8] 0 0
Percent Change from Baseline in Fasting Insulin
Timepoint [8] 0 0
Baseline, Week 80
Secondary outcome [9] 0 0
Change from Baseline in Short Form version 2 (SF-36v2) Acute Form Physical Function Domain Score
Timepoint [9] 0 0
Baseline, Week 80
Secondary outcome [10] 0 0
Pharmacokinetics (PK): Steady State Area Under the Concentration Time Cure (AUC)
Timepoint [10] 0 0
Baseline to Week 80

Eligibility
Key inclusion criteria
* Have a body mass index (BMI) =35.0 kilogram/square meter (kg/m²).
* Have established cardiovascular (CV) disease with at least 1 of the following:

* prior myocardial infarction
* prior ischemic or hemorrhagic stroke, or
* symptomatic peripheral arterial disease
* Have a history of at least 1 self-reported unsuccessful dietary effort to reduce body weight.
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
* Have had acute myocardial infarction, stroke, coronary revascularization, hospitalization for unstable angina, or hospitalization due to congestive heart failure within 90 days prior to screening.
* Have taken weight loss drugs, including over-the-counter medications, within 90 days prior to screening.
* Have a prior or planned surgical treatment of obesity.
* Have a change in body weight greater than 5 kg (11 pounds) within 90 days prior to screening.
* Have Type 1 diabetes.
* Have family or personal history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN-2)
* Have had pancreatitis.

Study design
Purpose of the study
Treatment
Allocation to intervention
Randomised controlled trial
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Blinded (masking used)
Who is / are masked / blinded?
The people receiving the treatment/s


The people analysing the results/data
Intervention assignment
Parallel
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
30/05/2023
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
17/02/2026
Actual
Sample size
Target
1800
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
ACT,NSW,QLD,SA,South AustVIC,WA
Recruitment hospital [1] 0 0
Canberra Hospital - Canberra
Recruitment hospital [2] 0 0
Emeritus Research - Botany
Recruitment hospital [3] 0 0
Northern Beaches Clinical Research - Brookvale
Recruitment hospital [4] 0 0
The AIM Centre / Hunter Diabetes Centre - Merewether
Recruitment hospital [5] 0 0
University of Sydney - Charles Perkins Centre - Sydney
Recruitment hospital [6] 0 0
Royal Brisbane and Women's Hospital - Brisbane
Recruitment hospital [7] 0 0
Core Research Group - Brisbane
Recruitment hospital [8] 0 0
CDH Research Institute - Maroochydore
Recruitment hospital [9] 0 0
Logan Hospital - Meadowbrook
Recruitment hospital [10] 0 0
Fusion Clinical Research - Adelaide
Recruitment hospital [11] 0 0
Southern Adelaide Diabetes & Endocrine Services - Mount Gambier
Recruitment hospital [12] 0 0
Southern Adelaide Diabetes & Endocrine Services - Oaklands Park
Recruitment hospital [13] 0 0
Nightingale Research - Adelaide
Recruitment hospital [14] 0 0
Box Hill Hospital - Box Hill
Recruitment hospital [15] 0 0
Emeritus Research - Camberwell
Recruitment hospital [16] 0 0
Barwon Health - Geelong
Recruitment hospital [17] 0 0
Austin Health - Repatriation Hospital - Heidelberg West
Recruitment hospital [18] 0 0
One Clinical Research - Nedlands
Recruitment postcode(s) [1] 0 0
2605 - Canberra
Recruitment postcode(s) [2] 0 0
2019 - Botany
Recruitment postcode(s) [3] 0 0
2100 - Brookvale
Recruitment postcode(s) [4] 0 0
2291 - Merewether
Recruitment postcode(s) [5] 0 0
2006 - Sydney
Recruitment postcode(s) [6] 0 0
4029 - Brisbane
Recruitment postcode(s) [7] 0 0
4064 - Brisbane
Recruitment postcode(s) [8] 0 0
4558 - Maroochydore
Recruitment postcode(s) [9] 0 0
4131 - Meadowbrook
Recruitment postcode(s) [10] 0 0
5000 - Adelaide
Recruitment postcode(s) [11] 0 0
5290 - Mount Gambier
Recruitment postcode(s) [12] 0 0
5046 - Oaklands Park
Recruitment postcode(s) [13] 0 0
3128 - Box Hill
Recruitment postcode(s) [14] 0 0
3124 - Camberwell
Recruitment postcode(s) [15] 0 0
3220 - Geelong
Recruitment postcode(s) [16] 0 0
3081 - Heidelberg West
Recruitment postcode(s) [17] 0 0
6009 - Nedlands
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
Connecticut
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Hawaii
Country [6] 0 0
United States of America
State/province [6] 0 0
Idaho
Country [7] 0 0
United States of America
State/province [7] 0 0
Illinois
Country [8] 0 0
United States of America
State/province [8] 0 0
Indiana
Country [9] 0 0
United States of America
State/province [9] 0 0
Iowa
Country [10] 0 0
United States of America
State/province [10] 0 0
Kansas
Country [11] 0 0
United States of America
State/province [11] 0 0
Massachusetts
Country [12] 0 0
United States of America
State/province [12] 0 0
Missouri
Country [13] 0 0
United States of America
State/province [13] 0 0
Nevada
Country [14] 0 0
United States of America
State/province [14] 0 0
New Jersey
Country [15] 0 0
United States of America
State/province [15] 0 0
New York
Country [16] 0 0
United States of America
State/province [16] 0 0
North Carolina
Country [17] 0 0
United States of America
State/province [17] 0 0
Ohio
Country [18] 0 0
United States of America
State/province [18] 0 0
Pennsylvania
Country [19] 0 0
United States of America
State/province [19] 0 0
South Carolina
Country [20] 0 0
United States of America
State/province [20] 0 0
Texas
Country [21] 0 0
United States of America
State/province [21] 0 0
Utah
Country [22] 0 0
United States of America
State/province [22] 0 0
Washington
Country [23] 0 0
Argentina
State/province [23] 0 0
Buenos Aires
Country [24] 0 0
Argentina
State/province [24] 0 0
Ciudad Aut
Country [25] 0 0
Argentina
State/province [25] 0 0
Ciudad Autónoma De Buenos Aires
Country [26] 0 0
Argentina
State/province [26] 0 0
Ciudad Autónoma De Buenos Aire
Country [27] 0 0
Argentina
State/province [27] 0 0
Córdoba
Country [28] 0 0
Argentina
State/province [28] 0 0
La Pampa
Country [29] 0 0
Argentina
State/province [29] 0 0
Mendoza
Country [30] 0 0
Argentina
State/province [30] 0 0
Santa Fe
Country [31] 0 0
Argentina
State/province [31] 0 0
Santiago D
Country [32] 0 0
Argentina
State/province [32] 0 0
Tucumán
Country [33] 0 0
Canada
State/province [33] 0 0
British Columbia
Country [34] 0 0
Canada
State/province [34] 0 0
Ontario
Country [35] 0 0
Canada
State/province [35] 0 0
Quebec
Country [36] 0 0
Hungary
State/province [36] 0 0
Csongrád
Country [37] 0 0
Hungary
State/province [37] 0 0
Fejér
Country [38] 0 0
Hungary
State/province [38] 0 0
Nyíregyháza
Country [39] 0 0
Hungary
State/province [39] 0 0
Nógrád
Country [40] 0 0
Hungary
State/province [40] 0 0
Somogy
Country [41] 0 0
Hungary
State/province [41] 0 0
Veszprém
Country [42] 0 0
Hungary
State/province [42] 0 0
Zala
Country [43] 0 0
Hungary
State/province [43] 0 0
Budapest
Country [44] 0 0
Hungary
State/province [44] 0 0
Debrecen
Country [45] 0 0
Hungary
State/province [45] 0 0
Zalaegerszeg
Country [46] 0 0
Mexico
State/province [46] 0 0
Baja California
Country [47] 0 0
Mexico
State/province [47] 0 0
Distrito Federal
Country [48] 0 0
Mexico
State/province [48] 0 0
Hidalgo
Country [49] 0 0
Mexico
State/province [49] 0 0
Jalisco
Country [50] 0 0
Mexico
State/province [50] 0 0
Nuevo León
Country [51] 0 0
Mexico
State/province [51] 0 0
Yucatán
Country [52] 0 0
Mexico
State/province [52] 0 0
Chihuahua
Country [53] 0 0
Mexico
State/province [53] 0 0
Durango
Country [54] 0 0
Mexico
State/province [54] 0 0
San Luis Potosí
Country [55] 0 0
Mexico
State/province [55] 0 0
Veracruz
Country [56] 0 0
Poland
State/province [56] 0 0
Mazowieckie
Country [57] 0 0
Poland
State/province [57] 0 0
Malopolskie
Country [58] 0 0
Poland
State/province [58] 0 0
Podlaskie
Country [59] 0 0
Poland
State/province [59] 0 0
Pomorskie
Country [60] 0 0
Poland
State/province [60] 0 0
Warminsko-mazurskie
Country [61] 0 0
Poland
State/province [61] 0 0
Lódzkie
Country [62] 0 0
Poland
State/province [62] 0 0
Slaskie
Country [63] 0 0
Puerto Rico
State/province [63] 0 0
Ponce
Country [64] 0 0
Puerto Rico
State/province [64] 0 0
San Juan
Country [65] 0 0
Slovakia
State/province [65] 0 0
Banskobystrický Kraj
Country [66] 0 0
Slovakia
State/province [66] 0 0
Bratislavský Kraj
Country [67] 0 0
Slovakia
State/province [67] 0 0
Košický Kraj
Country [68] 0 0
Slovakia
State/province [68] 0 0
Prešovský Kraj
Country [69] 0 0
Slovakia
State/province [69] 0 0
Bratislava
Country [70] 0 0
Slovakia
State/province [70] 0 0
Žilinský Kraj
Country [71] 0 0
Spain
State/province [71] 0 0
A Coruña [La Coruña]
Country [72] 0 0
Spain
State/province [72] 0 0
Andalucía
Country [73] 0 0
Spain
State/province [73] 0 0
Balears [Baleares]
Country [74] 0 0
Spain
State/province [74] 0 0
Barcelona [Barcelona]
Country [75] 0 0
Spain
State/province [75] 0 0
Cantabria
Country [76] 0 0
Spain
State/province [76] 0 0
Cádiz
Country [77] 0 0
Spain
State/province [77] 0 0
Lleida [Lérida]
Country [78] 0 0
Spain
State/province [78] 0 0
Sevilla
Country [79] 0 0
Spain
State/province [79] 0 0
Valenciana, Comunitat
Country [80] 0 0
Spain
State/province [80] 0 0
Madrid

Funding & Sponsors
Primary sponsor type
Commercial sector/industry
Name
Eli Lilly and Company
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The main purpose of this study is to evaluate the efficacy and safety of retatrutide once weekly in participants with obesity and established cardiovascular disease (CVD). The study will last about 113 weeks.
Trial website
https://clinicaltrials.gov/study/NCT05882045
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)
Address 0 0
Eli Lilly and Company
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
There may be multiple sites in this clinical trial -877-CTLILLY (1-877-285-4559) or
Address 0 0
Country 0 0
Phone 0 0
1-317-615-4559
Fax 0 0
Email 0 0
[email protected]
Contact person for scientific queries



Summary Results

For IPD and results data, please see https://clinicaltrials.gov/study/NCT05882045